R&D Pipeline

R&D Pipeline Pipeline (2021-2030)

Pipeline (2021-2030)

Oncology - Preclinical (67)

Modality Indication Targets Stage Company Project No. Detail
1 Nonclinical Safety and Efficacy Validation of a Novel Photosensitizer (MPP100) for the Treatment of Cervical Dysplasia and Approval of an Investigational New Drug (IND) Application
Small molecules Cervical intraepithelial neoplasia (CIN1-3) & HPV infection HPV-infected dysplastic and hyper-proliferative squamous cells within CIN lesions. Overexpressed LDL Preclinical Dr. inB Inc. RS-2026-25503500
2 Preclinical Development of an Oral Small-Molecule PD-L1 Immune Checkpoint Inhibitor for Cancer Therapy
Small molecules Solid tumor PD-L1 Preclinical ILAb Co. Ltd., RS-2026-25502303
3 Development of Next-Generation Cancer Therapeutics for the Inhibition of Pan-RAS Mutant Signaling
Small molecules CRC ACK1/GCK Preclinical MagicBullet Therapeutics RS-2026-25501930
4 Preclinical evaluation of the peptide candidate CBT-001-2334 for the development of CAIX-targeted radiopharmaceuticals for tumor diagnosis and therapy
RPT Solid tumor CAIX Preclinical C-BIOMEX RS-2026-25501541
5 PB203, A Triple-Target TME Disruptor (PD-L1/VEGF-A/PLGF): Next-generation immuno-oncology solution for pancreatic cancer, paving the way for refractory fibrotic/immune-excluded tumors.
Antibody PDAC (Gateway to NSCLC, TNBC, and immune-excluded/fibrotic solid tumors) PD-L1, VEGF-A, PLGF Preclinical Panolos Bioscience Inc. RS-2025-25455606
6 Non-Clinical Development of an Antibody-Drug Conjugate (ADC) Targeting RTK-like Receptors for the Treatment of Solid Tumors
Antibody Solid tumor undisclosed Preclinical Aimedbio Inc RS-2025-25455321
7 Development of a triple-function improved anti-GD2 CAR natural killer cell-based treatment for recurrent glioblastoma derived from induced pluripotent stem cells
Cell therapies Glioblastoma GD2 Preclinical Vigencell RS-2025-25455212
8 Pre-clinical development of JSC-441, a pan-KRAS inhibitor with KRAS-SOS1 interaction inhibition mechanism
Small molecules KRAS mutated cancers (NSCLC, CRC, PDAC) SOS1 Preclinical Jeil Pharmaceutical RS-2025-25455195
9 Preclinical Study for the Esophageal Cancer Treatment Technology Using the Mechanism of Cancer Cell-Selective Photodynamic Therapy with Next-Generation Photosensitizer HL270
Small molecules Esophageal cancer Photodynamic therapy Preclinical HANLIM PHARM.CO.,LTD RS-2025-25454976
10 Development of a Therapeutic Radiopharmaceutical using Alpha Nuclide Targeting mCRPC (Metastatic Castration Resistant Prostate Cancer)
RPT Metastatic Castration-Resistant Prostate Cancer (mCRPC) Prostate-Specific Membrane Antigen (PSMA) Preclinical CellBion Co., Ltd. RS-2025-25454770
11 Non-clinical trial and IND approval of high efficiency BCMA CAR-T cell therapy
Cell therapies Multiple Myeloma BCMA Preclinical nSAGE RS-2025-25454748
12 Development of innovative anti-cancer treatment through tumor microenvironment-specific targeting
rProtein Solid tumors TGF-β and *** Preclinical MedPacto, Inc. RS-2025-25449690
13 Development of BCMA-targeting CAR-MILs for Treatment of Relapsed/Refractory Multiple Myeloma
Cell therapies Multiple Myeloma MILs (골수침윤림프구) Preclinical VAXCELLBIO CO., LTD. RS-2025-02223662
14 Development of a Therapeutic Antibody Targeting TCTP for Refractory Colorectal Cancer
Antibody Colon cancer TCTP Preclinical 넥스아이 RS-2025-02213729
15 Non-clinical development of an antibody-drug conjugate(ADC) for solid tumors targeting Src kinase-related transmembrane proteins
Antibody Solid cancer Target A Preclinical Aimedbio Inc. RS-2025-02213655
16 DWP223: A Selective DNA Polymerase Theta Inhibitor
Small molecules BRCA mutated solid cancer POLQ Preclinical Daewoong Pharmaceutical RS-2025-02213327
17 Phase 1 IND Approval for Next-Generation Functionally Enhanced Tumor Infiltrating Lymphocyte (TIL) Cell Therapy for Recurrent Ovarian Cancer
Cell therapies Ovarian cancer MUC-1 peptide stimulation Preclinical CHA Biotech Co., Ltd RS-2025-02213314
18 IND Approval of Novel Immunotherapy for NHL: Intratumoral Administration of Novel Adjuvant ProLNG-001 and/or Personalized Cancer Vaccine ProV-001
Other-Bio. non-Hodgkin lymphoma BCR 가변영역 Preclinical Progeneer Inc. RS-2025-02122974
19 Non-Clinical Study of CD19 CAR-NK for Phase 1 Clinical Trial for Hematologic Malignancy
Cell therapies B- cell lymphoma CD19 Preclinical GC Cell RS-2024-00463361
20 Development of DWP216, a TEAD1 selective inhibitor for NF2 mutant solid cancer patients
Small molecules Solid cancer (NF2 mutant, EGFR mutant, KRAS mutant) TEAD1 Preclinical Daewoong Pharmaceutical Co., LTD RS-2024-00462280
21 "Preclinical development of a bispecific aPD-1/IL-2v immunotherapy with enhanced TME selectivity and safety via modulated IL-2Rγ affinity"
Antibody Solid tumor PD-1, IL-2 receptor in activated T cells Preclinical MustBio RS-2024-00459772
22 CKD-ADC, A Novel Antibody-Drug Conjugate Targeting cMET in Solid Tumors
Antibody Non-small cell lung cancer cMET Preclinical Chong Kun Dang Pharmaceutical Corp. RS-2024-00442212
23 Development of CK1α selective molecular glue degrader for p53 wild-type solid cancer ONCOLOGY
TPD ACC, CRC CK1-alpha degrader Preclinical Pin Therapeutics Inc. RS-2024-00441932
24 Non-clinical Development of gene therapy drug candidates based on oncospreading retroviral vectors
Gene & Nucleic acids Glioblastoma TK & CD genes Preclinical [a:rtiCure] RS-2024-00338747
25 Nonclinical studies of therapeutic radiopharmaceuticals for ovarian cancer based on nano-drug carriers for global market entry
RPT Ovarian cancer Folate receptor Preclinical ZTI BIOSCIENCES, INC RS-2024-00337888
26 Development of peptide vaccine against the glioblastoma with CMV pp65
rProtein GBM Glioblastoma, multifocal N/A Preclinical NA Vaccine Institute RS-2024-00337146
27 Nonclinical development of CTN001 for treating patients with breast cancer and gastric cancer
Antibody Breast cancer, Gastric cancer HER2 Preclinical Centenaire Bioscience, Inc. RS-2024-00336882
28 Completion of CMC, GLP-tox Testing, Clinical Trial Medication Production, and IND Approval for Orally Administerable CD39 Target Inhibitor Preclinical Candidate Substance
Small molecules Colorectal cancer CD39 Preclinical SCBIO Inc. RS-2024-00336376
29 Phase 2 IND approval of high purity immune cell therapy (CBT101) of frozen formulation for recurrent glioblastoma, improved through process advancement
Cell therapies Recurrent glioblastoma Preclinical CHABIOTECH CO.,LTD RS-2024-00334310
30 Non.clinical development of C2.558, a SOS1 inhibitor, for the treatment of patients with KRAS mutant solid tumors
Small molecules Solid tumor KRAS.SOS1 PPI Preclinical Cyrus Therapeutics Inc. RS-2023-00283208
31 Non.clinical development of CYRS1542, a GSPT1 Molecular Glue Degrader, for the treatment of patients with SCLC and AML
TPD SCLC, AML GSPT1 Preclinical Cyrus Therapeutics Inc. RS-2023-00282972
32 Preclinical Development of Anti.FGFR3 ADC for the Treatment of Bladder Cancer and Brain Tumor
Antibody Glioblastoma FGFR3 Preclinical Aimedbio RS-2023-00282706
33 Development of HLA.G CAR.T cell therapy targeting HLA.G.positive solid tumors
Cell therapies Solid tumor HLA.G Preclinical HK Inno. N RS-2023-00282541
34 Preclinical development of a MET degrader as a novel NSCLC agent
TPD NSCLC MET (a receptor tyrosine kinase) Preclinical InnoCure Therapeutics RS-2023-00259138
35 Nonclinical development of AR degrader UBX.103335 for the treatment of metastatic castration.resistant prostate cancer
TPD Castration.resistant prostate cancer Androgen receptor (AR) Preclinical Ubix Therapeutics RS-2023-00258142
36 Preclinical study of CLDN18.2 targeting antibody-drug conjugate for gastric cancer treatment
Antibody Gastric cancer, Gastroesophageal junction edema cancer CLDN18.2 Preclinical AbTis Co., Ltd. RS-2023-00219493
37 Pre-clinical development of SCB0020160, a Sirt6 agonist with a potent anti-cancer effect
Small molecules pancreatic cancer SIRT6 Preclinical SCBIO RS-2023-00218894
38 Development of Immunoferritin Cellem001 with Dual Immune Checkpoints Blockade and T/NK-tumor Cell Engager
rProtein NSCLC, Melanoma PD-L1, TIGIT Preclinical Cellemedy RS-2023-00218402
39 Non-clinical studies of VRN101099, a brain permeable HER2 selective kinase inhibitor
Small molecules Breast cancer, Colon cancer HER2 Preclinical VORONOI RS-2023-00217541
40 Non-clinical study of NRT-YHD-001 as macrophage immune check point blocker in liver cancer
Gene & Nucleic acids Liver cancer let-7i-5p miRNA Preclinical NEORNAT Inc. RS-2023-00217374
41 Pre-clinical development of anticancer candidate to treat small cell lungcancer (SCLC) through PROTAC-based PLK1 protein degradation
TPD NSCLC PLK1 Preclinical UPPPTHERA RS-2022-00167113
42 Non-clinical study and IND approval of GI-108, a metabolic immune anti-cancer drug
rProtein Solid Tumor CD73, IL-2 Preclinical GI Innovation, Inc RS-2022-00166700
43 Non-clinical Development of SREBP1 Degrader for the Cancer Stem Cell-targeted Treatment of Glioblastoma
Small molecules Glioblastoma SCAP:SREBP1 Preclinical MEDIFIC RS-2022-00166323
44 IND approval and securing IMP batch for GENA-104A16, an immune checkpoint inhibitor targeting CNTN4
Antibody Solid Tumor CNTN4 Preclinical Genome&Company RS-2022-00166157
45 Non-clinical study on the development of customized targeted anticancer agent for the treatment of advanced Hepatocellular Carcinoma
Small molecules Liver cancer FLT3/VEGFR2/PDGFRb TK Preclinical Etnova Therapeutics RS-2022-00165725
46 Preclinical study for the development of MRI contrast agent of innovative artificial melanin
Others-Synth. Diagnostic Liver, Kidney Preclinical BL Melanis RS-2022-00165594
47 Non-clinical development of long-acting IL-2 analog (HM16390) with optimized IL-2 receptor binding property
rProtein Renal cell carcinoma, melanoma IL-2 Preclinical Hanmi Pharm. Co., Ltd. RS-2022-00165557
48 An Oral, Selective, and Potent EGFR Mutant Protein Degrader for the Treatment of NSCLC
TPD NSCLC(EGFR mutation) EGFR Preclinical J2H Biotech HN22C0670
49 Non-clinical study of VRN11, a CNS-penetrable inhibitor for EGFR
G719X, L861X, S768I/V as well as C797S mutation NSCLC patients
Small molecules NSCLC(EGFR mutation) EGFR Preclinical Voronoi, Inc HN22C0663
50 Preclinical study of DA-4505 for the treatment of cancer immunotherapy
Small molecules Advanced Solid Tumor AhR Preclinical DONG-A ST HN22C0630
51 JW2286, a novel inhibitor directly targeting of STAT3, drug discovery for solid cancer including triple negative cancer
Small molecules TNBC STAT3 Preclinical JW Pharmaceutical HN22C0583
52 ENPP1 Inhibitor TXN10128
Small molecules Colorectal cancer ENPP1 Preclinical TXINNO Bioscience Inc HN22C0531
53 Preclinical development of ITC-6146RO, a B7-H3 targeting ADC, for the Treatment of Non-Small Cell Lung Cancer
Antibody NSCLC B7-H3 Preclinical IntoCell HN22C0373
54 Development of gene therapy for NMIBC using bispecific RNAi
Gene & Nucleic acids Bladder Cancer, Head And Neck Cancer, Pancreatic Cancer mTOR, STAT3 Preclinical Curigin HN22C0365
55 Preclinical Development of LEM-S403 Targeting Tumor Microenvironment Immune Modulation of Immune Checkpoint Inhibitor Non-Responsive Solid Tumor
Gene & Nucleic acids Solid Tumor IDO1 Preclinical Lemonex Inc. HN22C0262
56 Development of L1CAM targeted CAR-T therapy for recurrent ovarian cancer
Cell therapies Ovarian Cancer L1CAM Preclinical Cartexell Inc HN22C0250
57 Development of a first-in-class immunotherapy for treatment of non-small cell lung cancer with PD-L1 negative/low
Antibody Lung Cancer IGSF1 Preclinical Wellmarkerbio HN22C0157
58 Nonclinical study of the immuno-oncological therapeutic antibody against novel immune checkpoint CD300c
Antibody Lung cancer, Colorectal, Breast cancer CD300c Preclinical CentricsBio Inc. HN21C1400
59 Preclinical study of IOH-001, a Bispecific Antibody immunotherapy targeting PD-L1 and CD47
Antibody TNBC PD-L1, CD47 Preclinical ImmuneOncia HN21C1388
60 Production of non-clinical and clinical samples of TROP2-ADC for IND filing and approval, or technology transfer
Antibody Solid Tumor TROP2 Preclinical LegoChem Biosciences, Inc. HN21C1199
61 Non-clinical development of HM97662, an epigenetic protein EZH1/2 dual inhibitor, as a treatment for various cancers
Small molecules Malignant tumor EZH1/2 Preclinical Hanmi Pharm. Co., Ltd. HN21C1077
62 Pre-clinical Studies and IND Approval of First-in-class Cancer Stemness Blocking Anti-Cancer Agent, PMB212
Small molecules Resistant cancer PIN1 Preclinical PimedBio HN21C0955
63 Preclinical study of JPC-089, a blood cancer treatment targeting PIM kinase
Small molecules AML PIM Kinase Preclinical Jeil Pharmaceutical CO.,LTD. HN21C0886
64 NN3201, an IND-enabling study stage multimodal, cKIT-targeting ADC for SCLC, GIST, and AML
Antibody Gastrointestinal stromal tumor C-kit, microtuble inhibition에 의한 cell cycle arrest, apoptosis 유도 Preclinical Novelty Nobility Inc. HN21C0860
65 Development of anti-VISTA antibody PMC-309 for the treatment of NSCLC
Antibody NSCLC VISTA Preclinical PharmAbcine Inc. HN21C0774
66 ABL103, A novel T-cell engaging bispecific antibody, exhibits potent in vitro and vivo antitumor activity and low toxicity via B7-H4 dependent 4-1BB activation in tumor microenvironment
Antibody Solid Tumor B7-H4, 4-1BB Preclinical ABLBio HN21C0614
67 Non-clinical study of VRN08, an oral Mps1 inhibitor to modulate SAC for advanced solid tumor
Small molecules TNBC and CDK4/6i resistant solid tumors Mps1 Preclinical Voronoi Inc. HN21C0580
BACK